Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

BACKGROUND: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). METHODS: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240591/
https://www.ncbi.nlm.nih.gov/pubmed/35785245
http://dx.doi.org/10.1177/20406207221104584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240591/
https://www.ncbi.nlm.nih.gov/pubmed/35785245
http://dx.doi.org/10.1177/20406207221104584

Ejemplares similares